Recurrent cardiotoxicity in a fluoropyrimidine treated cancer patient – case report and practical recommendations
Abstract
Keywords
Full Text:
PDFReferences
Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? Cancer Treat Rev. 2016;50:23-34. doi: 10.1016/j.ctrv.2016.08.002. PMID: 27589829.
Deac AL, Burz CC, Bocşe HF, Bocşan IC, Buzoianu AD. A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment. Med Pharm Rep. 2020;93(3):223-230. doi: 10.15386/mpr-1564. PMID: 32832886; PMCID: PMC7418836.
Yuan C, Parekh H, Allegra C, George TJ, Starr JS. 5-FU induced cardiotoxicity: case series and review of the literature. Cardio-Oncology. 2019;5:13. Doi: 10.1186/s40959-019-0048-3. PMID: 32154019; PMCID: PMC7048125.
Quaranta S, Thomas F. Pharmacogenetics of anti-cancer drugs: state of the art and implementation – recommendations of the French National Network of Pharmacogenetics. Therapie. 2017;72(2):205-215. 10.1016/j.therap.2017.01.005. PMID: 28262261
van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939-950. doi: 10.1016/j.ejca.2003.12.004. PMID: 15093568.
Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639-1650. doi: 10.1016/S1470-2045(15)00286-7. PMID: 26603945.
Boisdron-Celle M, Capitain O, Faroux R, et al. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach. Semin Oncol. 2017;44(1):13-23. doi: 10.1053/j.seminoncol.2017.02.008. PMID: 28395758.
Kanduri J, More LA, Godishala A, Asnani A. Fluoropyrimidine-Associated Cardiotoxicity. Cardiol Clin. 2019;37(4):399-405. doi: 10.1016/j.ccl.2019.07.004. PMID: 31587781.
Sara JD, Kaur J, Khodadadi R, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140. doi: 10.1177/1758835918780140. PMID: 29977352; PMCID: PMC6024329.
Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974-984. doi: 10.1016/j.ctrv.2013.03.005. PMID: 23582737.
Karabay CY, Gecmen C, Aung SM, et al. Is 5-fluorouracil-induced vasospasm a Kounis syndrome? A diagnostic challenge. Perfusion. 2011;26(6):542-545. doi: 10.1177/0267659111410347. PMID: 21628340.
Shoemaker LK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control. 2004;11(1):46-9. doi: 10.1177/107327480401100207. PMID: 14749623.
Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53(13):3028-3033. PMID: 8391384.
Thyss A, Gaspard MH, Marsault R, et al. Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. Ann Oncol. 1992;3(1):88. doi: 10.1093/oxfordjournals.annonc.a058084. PMID: 1606078.
Clasen SC, Ky B, O'Quinn R, et al. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol. 2017;8(6):970-979. doi: 10.21037/jgo.2017.09.07. PMID: 29299356; PMCID: PMC5750187.
Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75-82. doi: 10.1007/s00432-007-0250-9. PMID: 17636329.
Ison G, Beaver JA, McGuinn WD Jr, et al. FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs. Clin Cancer Res. 2016;22(18):4545-9. doi: 10.1158/1078-0432.CCR-16-0638. PMID: 27401247.
DOI: http://dx.doi.org/10.22551/2023.39.1002.10241
Copyright (c) 2023 Andrada Larisa Deac, Raluca Maria Pop, Cristina Florina Crisan, Claudia Cristina Burz, Anca Dana Buzoianu
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
ISSN: 2360-6975